Drug Eluting Balloon Market by Type, Coating Technology, End User

Description

List of Tables

[198 Pages Report] The Drug Eluting Balloon Market size was estimated at USD 965.84 million in 2023 and expected to reach USD 1,098.31 million in 2024, at a CAGR 15.51% to reach USD 2,650.47 million by 2030.

A drug eluting balloon (DEB) is an innovative medical device designed for use in angioplasty procedures to treat narrowed or blocked arteries. This catheter-based technology incorporates a balloon at its tip, which is coated with an anti-proliferative medication. When the balloon is inflated within the affected artery, it mechanically dilates the vessel to restore blood flow and also delivers the therapeutic agent directly to the arterial walls. This local drug delivery helps prevent restenosis, the re-narrowing of the artery, by inhibiting the growth of neointimal hyperplasia, a common cause of vessel re-occlusion. DEBs provide a targeted pharmacological approach that complements the mechanical intervention, offering an alternative to traditional therapies such as bare-metal or drug-eluting stents. The growth of the drug eluting balloon market is primarily driven by the rising prevalence of cardiovascular diseases globally and the subsequent increase in demand for minimally invasive surgical procedures. However, the stringent regulatory approval processes can impede the market's progression. Additionally, high costs associated with DEB treatments may deter potential markets in developing countries. Despite challenges, technological advancements improving the efficacy and safety of DEBs, along with enhanced patient recovery times, present future market opportunities. Rising reimbursement policies favoring DEB procedures in developing nations create new avenues for market expansion.

KEY MARKET STATISTICS
Base Year [2023]	USD 965.84 million
Estimated Year [2024]	USD 1,098.31 million
Forecast Year [2030]	USD 2,650.47 million
CAGR (%)	15.51%

Type: Significance of coronary DEBs in enhancing deliverability and drug transfer

Coronary drug eluting balloons (DEBs) is an innovative medical device used in percutaneous coronary interventions (PCIs) to treat coronary artery disease. They are carefully designed to deliver anti-proliferative drugs directly to the site of arterial blockage, facilitating the inhibition of neointimal hyperplasia and thus preventing restenosis. Peripheral drug eluting balloons are deployed to treat peripheral artery disease (PAD), particularly in the femoral and popliteal arteries. Similar to their coronary counterparts, these DEBs release medication that helps prevent restenosis by minimizing the growth of the vascular smooth muscle tissue.

Coating Technology: Growing preferences for enduraCoat with better local drug release profile

EnduraCoat technology is a coating designed to provide a uniform and controlled drug transfer to the arterial wall. This technology typically offers a durable, low-dose coating that minimizes particulate loss and ensures a consistent drug release profile. FreePac is a type of coating that combines a synthetic polymer and an antiproliferative drug, ensuring consistent drug transfer and bioavailability. FreePac is typically designed to address the challenges of restenosis in peripheral arterial disease. Paccocath technology incorporates a mixture of a chemotherapeutic drug and a specific excipient encapsulated within a matrix. This matrix coating allows for controlled drug release to the target lesion, preventing neointimal hyperplasia. TransPax is a newer coating technology that uses a bioresorbable carrier for drug delivery. TransPax may be preferred for patients who could benefit from a bioresorbable drug delivery system. This system is potentially advantageous where the long-term presence of non-resorbable polymers can be undesirable.

End User: Higher adoption of DEBs in Cath Labs owing to ease of use and speed of the procedure

Ambulatory surgery centers (ASCs) prioritize DEBs owing to their focus on outpatient surgical care, where efficiency and patient turnover are key factors. Patients benefit from the minimally invasive nature of DEB procedures, which aligns with the ASC model of reducing hospital stays and promoting quick recovery. Cath labs are specialized hospital units or stand-alone facilities where cardiac catheterizations and other endovascular procedures are performed. DEBs are preferred in these facilities for their ability to reduce the likelihood of restenosis without the long-term commitment of a stent. Hospitals represent the broadest end-user segment for DEBs owing to the variety of services offered and patient cases handled. Hospitals require DEBs that are versatile and can be used for complex and high-risk patient populations.

Regional Insights

In the Americas, the market for drug-eluting balloons (DEBs) has been experiencing robust growth driven by several factors, including the rising prevalence of peripheral and coronary artery diseases and increased awareness of the benefits of DEBs over traditional therapies. The United States is a major contributor in this region owing to its advanced healthcare infrastructure, favorable reimbursement policies, and presence of significant market players. The region's growth is further supported by numerous clinical trials and research studies validating the efficacy and safety of DEB therapy. The EMEA region presents a diverse market landscape for DEBs. In Europe, the adoption of DEBs is gaining momentum, especially in Western European countries, with higher accessibility to new medical devices and a strong presence of established companies. The Middle East and Africa present untapped opportunities with gradual growth, propelled by improving healthcare infrastructure and increasing investment in the healthcare sector. The Asia-Pacific market for DEBs is showing significant growth potential, with the burgeoning population, the increasing incidence of diabetes-induced vascular diseases, and escalating healthcare expenditures. Moreover, APAC's market is being stimulated by the rising number of local manufacturers and favorable government initiatives to enhance healthcare infrastructure.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Drug Eluting Balloon Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Drug Eluting Balloon Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Drug Eluting Balloon Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, B. Braun Melsungen AG, Balton Sp. z o. o., Bayer AG, Becton, Dickinson and Company, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Cardionovum GmbH, Concept Medical, Cook Medical, Inc., Eurocor Tech GmbH, Invamed, iVascular S.L.U., Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Laborie Medical Technologies, Inc., Lepu Medical Technology, M.A. Med Alliance SA by Cordis Corporation, Medtronic PLC, SurModics, Inc., Terumo Corporation, Wellinq, and Zylox-Tonbridge Medical Technology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Drug Eluting Balloon Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Coronary Drug Eluting Balloon
- Peripheral Drug Eluting Balloon

Coating Technology
- EnduraCoat
- FreePac
- Paccocath
- TransPax

End User
- Ambulatory Surgery Centers
- Cath Labs
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Drug Eluting Balloon Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Drug Eluting Balloon Market?

3. What are the technology trends and regulatory frameworks in the Drug Eluting Balloon Market?

4. What is the market share of the leading vendors in the Drug Eluting Balloon Market?

5. Which modes and strategic moves are suitable for entering the Drug Eluting Balloon Market?

Product Code: MRR-4348D129FA8E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Geriatric Population Leading to Cardiovascular Diseases
  - 5.1.1.2. Rising Prevalence of Peripheral and Coronary Artery Diseases
  - 5.1.1.3. Favorable Approvals to Support the Growth of DEBs
- 5.1.2. Restraints
  - 5.1.2.1. Issues Associated to Product Recalls of Drug-Eluting Balloons
- 5.1.3. Opportunities
  - 5.1.3.1. New Developments in the Clinical Use of Drug-Coated Balloon Catheters
  - 5.1.3.2. Advancement, Innovation, and Research in Drug-Coated Balloons
- 5.1.4. Challenges
  - 5.1.4.1. Lack of Availability for Skilled and Trained Professionals
5.2. Market Segmentation Analysis
- 5.2.1. Type: Significance of coronary DEBs in enhancing deliverability and drug transfer
- 5.2.2. Coating Technology: Growing preferences for enduraCoat with better local drug release profile
- 5.2.3. End User: Higher adoption of DEBs in Cath Labs owing to ease of use and speed of the procedure
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Drug Eluting Balloon Market, by Type

6.1. Introduction
6.2. Coronary Drug Eluting Balloon
6.3. Peripheral Drug Eluting Balloon

7. Drug Eluting Balloon Market, by Coating Technology

7.1. Introduction
7.2. EnduraCoat
7.3. FreePac
7.4. Paccocath
7.5. TransPax

8. Drug Eluting Balloon Market, by End User

8.1. Introduction
8.2. Ambulatory Surgery Centers
8.3. Cath Labs
8.4. Hospitals

9. Americas Drug Eluting Balloon Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Drug Eluting Balloon Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Drug Eluting Balloon Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Advanced NanoTherapies (ANT) Secures USD 4 Million Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD)
- 12.3.2. Translumina further Strengthens Its Technology Portfolio with Acquisition of Blue Medical Devices, Netherlands
- 12.3.3. Surmodics Receives FDA Approval for the SurVeil Drug-Coated Balloon

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio